EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

Chao Li iD, ChengXin Deng, Ping Wu, KaiFan Liu, Xin Huang, MingMin Li, XiaoMei Chen, SuXia Geng, PeiLong Lai, JianYu Weng iD, Xin Du

Clinical and Translational Science · 2024-01 · 17 (1)

DOI: 10.1111/cts.13711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 10.01.2024. Verfasst von Chao Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs). The study's findings show promise: the HMAs plus Vene group ( n = 13, 53.8%) demonstrated superior overall response rates compared to the HMA monotherapy (mono) group ( n = 19, 31.6%) and HMA plus arsenic trioxide group ( n = 9, 22.2%) by the second cycle, and notably higher response rates (53.8% vs. 15.7%, p = 0.04) compared to the HMA mono group after four cycles. Over a median follow‐up of 14.7 months, the HMAs plus Vene group exhibited significantly lower cumulative mortality (23.1%) compared to the other two groups ( p = 0.003 and p = 0.008, respectively). Furthermore, this group displayed extended overall survival compared to the others. The study also delved into the molecular mechanisms, revealing significant BCL2 mRNA overexpression in patients with CMML. These findings suggest the potential for HMAs combined with Vene therapy in CMML but emphasize the necessity for further prospective studies to determine its precise role in managing CMML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicSulfonamidesBridged Bicyclo Compounds, HeterocyclicHumansRetrospective StudiesProspective Studies

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou, China.
  • Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

ORCID-Profile: Chao Li, JianYu Weng

Zitieren

APA

Li, C., Deng, C., Wu, P., Liu, K., Huang, X., Li, M., Chen, X., Geng, S., Lai, P., Weng, J., & Du, X. (2024). Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13711

Vancouver

Li C, Deng C, Wu P, Liu K, Huang X, Li M, et al. Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience. Clinical and Translational Science. 2024;17(1). doi:10.1111/cts.13711

BibTeX
@article{Li2024,
  author = {Li, Chao and Deng, ChengXin and Wu, Ping and Liu, KaiFan and Huang, Xin and Li, MingMin and Chen, XiaoMei and Geng, SuXia and Lai, PeiLong and Weng, JianYu and Du, Xin},
  title = {Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1111/cts.13711}
}
Kostenlos starten →